Лучшие больницы для «Balloon Sinuplasty» в Хайдарабад, Индия

In India, Balloon Sinuplasty at a JCI- or NABH-accredited hospital typically costs between USD 1,500 and USD 3,500 for a bilateral multi-sinus procedure, inclusive of surgeon fees, facility charges, anaesthesia (if applicable), and standard post-operative medications. This range may increase by USD 500–1,000 if adjunct procedures such as septoplasty, concurrent microdebrider polypectomy, or steroid-eluting implant (Intersect ENT Propel) placement are performed. In the UAE — specifically at JCI-accredited facilities licensed by the Dubai Health Authority (DHA) or Abu Dhabi Department of Health (DOH) — the equivalent procedure is priced between USD 3,500 and USD 7,000, reflecting higher facility overhead, premium infrastructure, and the cost of living in the GCC. India is therefore approximately 50–60% less expensive than the UAE for the same procedure performed by fellowship-trained rhinologists using identical FDA-cleared balloon catheter platforms (Acclarent Relieva, Entellus FinESS). Both destinations are substantially more affordable than comparable procedures in the United States (USD 7,000–15,000) or the United Kingdom (GBP 5,000–10,000 privately). GAF Healthcare provides itemised cost estimates for both destinations based on the patient's specific CT findings and planned surgical scope within 48 hours of remote case review.

For straightforward bilateral Balloon Sinuplasty (BSP) without concurrent procedures, the minimum recommended post-operative stay before an international flight is 7–10 days. This timeline is determined by three clinical milestones: resolution of acute post-procedural mucosal oedema and bloody discharge (typically Days 3–5); a mandatory post-operative nasal endoscopy review by the treating ENT surgeon at Day 7–10 to confirm sinus ostial patency, absence of synechia formation, and no evidence of early infection or epistaxis risk; and the patient's ability to perform the Valsalva manoeuvre (equalise ear pressure during cabin pressurisation) comfortably without sinus pain. At cabin pressures equivalent to 8,000 feet altitude, the dilated and patent sinus ostia established by BSP actually equilibrate pressure more efficiently than pre-operatively obstructed sinuses — meaning well-healed BSP patients typically tolerate flying better than they did before surgery. If the Day 7–10 endoscopy is satisfactory, the GAF Healthcare medical team issues a formal fit-to-fly clearance letter. For hybrid BSP with concurrent FESS, polypectomy, or septoplasty, the minimum stay extends to 10–14 days to allow adequate mucosal healing. Patients travelling long-haul (> 8 hours flight time) are advised to stay a full 14 days to minimise the risk of in-flight epistaxis or sinus pressure pain.

Balloon Sinuplasty has a procedural technical success rate (confirmed intraoperative ostial dilation and patent drainage on post-procedural endoscopy) of approximately 98–99% in experienced hands. The clinically meaningful success rate — defined as a ≥ 20-point reduction in SNOT-22 (Sino-Nasal Outcome Test-22) score and the absence of revision surgery — is reported at 93–96% at 12 months and 85–90% at 24 months in the landmark REMODEL randomised controlled trial and the CLEAR multi-centre registry study. Ostial patency on follow-up CT or endoscopy is maintained in approximately 87% of treated sinuses at 2 years. The 10–15% revision rate at 2 years is predominantly concentrated in patients with nasal polyp-dominant CRS (CRSwNP), which is why GAF Healthcare's partner rhinologists rigorously evaluate polyp burden pre-operatively and — where appropriate — recommend pre-operative dupilumab (Dupixent) biological therapy to optimise mucosal status before balloon dilation. For isolated, non-polyp CRS (CRSsNP) with primary ostial obstruction on CT, BSP delivers durable symptom relief that is statistically non-inferior to conventional FESS at 2 years, with significantly faster recovery and lower peri-operative morbidity. The long-term durability of results is further supported by the post-operative regimen coordinated by GAF Healthcare: indefinite maintenance intranasal corticosteroid therapy, regular saline irrigation, and scheduled endoscopic surveillance reviews at 3, 12, and 24 months.